With major inflammation in the upper airways contributing to significant morbidity and death, asthma predominated as a common inflammatory illness mostly affecting the lower respiratory tract. A thorough investigation into potential novel treatment targets was ongoing.
The medications, such as β2-adrenergic agonists, muscarinic antagonists, and specific corticosteroids, ultimately remained the cornerstone for controlling asthma because the bulk of them failed in the studies. Numerous endogenous factors help to keep the lungs in their natural balance and stop the progression of the illness. One of these was the apolipoproteins, which are diverse sets of lipoprotein moieties that have an immunomodulatory function in a variety of diseases, in addition to assisting in the transport and metabolism of lipids. The immunomodulatory properties of apolipoproteins in chronic respiratory diseases like asthma and COPD were being linked by modern research, which may help to slow the disease’s progression.
Recent research has clarified how apoA-I and apoE act as protective factors in asthma. This has made it possible to use specific apolipoprotein-mimetic peptides in the long term to treat these severe pulmonary illnesses. For a study, researchers discussed the important and likely mechanistic functions of apolipoproteins, such as apoA-I, apoB, apoE, apoJ, and apoM, in the pathogenesis and management of asthma, as well as the development of apoA-I and apoE mimics as a key therapeutic approach for both eosinophilic and neutrophilic asthma with corticosteroid resistance.